Brigatinib (AP26113) Efficacy and Safety in ALK plus NSCLC: Phase 1/2 Trial Results

被引：0

作者：

Gettinger, Scott N. ^{[1
]}

Bazhenova, Lyudmila ^{[2
]}

Salgia, Ravi ^{[3
]}

Langer, Corey J. ^{[4
]}

Gold, Kathryn A. ^{[5
]}

Rosell, Rafael ^{[6
,7
]}

Shaw, Alice ^{[8
]}

Weiss, Glen J. ^{[9
]}

Dorer, David J. ^{[10
]}

Rivera, Victor M. ^{[10
]}

Conlan, Maureen G. ^{[10
]}

Kerstein, David ^{[10
]}

Camidge, Ross ^{[11
]}

机构：

[1] Yale Canc Ctr, New Haven, CT USA

[2] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[3] Univ Chicago Med, Chicago, IL USA

[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Dexeus Univ Inst, Barcelona, Spain

[7] Catalan Inst Oncol, Barcelona, Spain

[8] Massachusetts Gen Hosp, Boston, MA 02114 USA

[9] Canc Treatment Ctr Amer, Goodyear, AZ USA

[10] Ariad Pharmaceut Inc, Cambridge, MA USA

[11] Univ Colorado, Ctr Canc, Aurora, CO USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期

关键词：

NSCLC; TKI; brigatinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ORAL33.06

引用

页码：S238 / S239

页数：2

共 50 条

[41] Brigatinib (BRG) in ALK plus crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.
Gettinger, Scott N.
Huber, Rudolf M.
Kim, Dong-Wan
Bazhenova, Lyudmila
Hansen, Karin Holmskov
Tiseo, Marcello
Langer, Corey J.
Paz-Ares, Luis G.
West, Howard
Reckamp, Karen L.
Weiss, Glen J.
Smit, Egbert F.
Hochmair, Maximilian
Kim, Sang-We
Ahn, Myung-Ju
Kim, Edward S.
Groen, Harry J. M.
Pye, Joanna
Vranceanu, Florin
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[42] Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK1 NSCLC: Updated results from the phase III ALTA-1L trial
Camidge, R.
Kim, H. R.
Ahn, M-J.
Yang, J. C-H.
Han, J-Y.
Hochmair, M. J.
Lee, K. H.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D-W.
Griesinger, F.
Felip, E.
Califano, R.
Spira, A.
Gettinger, S.
Tiseo, M.
Ni, Q.
Zhang, P.
Popat, S.
ANNALS OF ONCOLOGY, 2019, 30
[43] Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI-naive ALK plus NSCLC: Final results from ALTA-1L
Popat, S.
Kim, H. R.
Ahn, M-J.
Yang, J. C.
Han, J-Y.
Hochmair, M. J.
Lee, K. H.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D-W.
Griesinger, F.
Felip, E.
Califano, R.
Spira, A.
Gettinger, S. N.
Tiseo, M.
Lin, H. M.
Liu, Y.
Vranceanu, F.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2021, 32 : S954 - S955
[44] Updated Efficacy/Safety Data From the Phase 2 NP28761 Study of Alectinib in ALK plus NSCLC
Shaw, Alice
West, Howard
Socinski, Mark A.
Ou, Ignatius
Gandhi, Leena
Gadgeel, Shirish
Belani, Chandra P.
Shirai, Keisuke
Bazhenova, Lyudmila
Santos, Edgardo
Riely, Gregory J.
Chiappori, Alberto
Cetnar, Jeremy
Mekhail, Tarek
Chao, Bo
Borghaei, Hossein
Gold, Kathryn A.
Johannsdottir, Hrefna
Ruf, Thorsten
Boisserie, Frederic
Henschel, Volkmar
Zeaiter, Ali
Camidge, Ross
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S237 - S238
[45] AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions.
Squillace, Rachel M.
Anjum, Rana
Miller, David
Vodala, Sadanand
Moran, Lauren
Wang, Frank
Clackson, Tim
Garner, Andrew P.
Rivera, Victor M.
CANCER RESEARCH, 2013, 73 (08)
[46] Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).
Kim, Dong-Wan
Tiseo, Marcello
Ahn, Myung-Ju
Reckam, Karen L.
Hansen, Karin Holmskov
Kim, Sang-We
Huber, Rudolf M.
West, Howard Jack
Groen, Harry J. M.
Hochmair, Maximilian J.
Leighl, Natasha B.
Gettinger, Scott N.
Lange, Corey J.
Paz-Ares, Luis G.
Smit, Egbert F.
Kim, Edward S.
Reichmann, William G.
Kerstein, David
Haluska, Frank G.
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[47] Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK plus NSCLC in the ALTA Trial
Camidge, D. R.
Tiseo, M.
Ahn, M.
Reckamp, K.
Hansen, K.
Kim, S.
Huber, R.
West, H.
Groen, H.
Hochmair, M.
Leighl, N.
Gettinger, S.
Langer, C.
Paz-Ares, L.
Smit, E.
Kim, E.
Reichmann, W.
Kerstein, D.
Kim, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1892 - S1892
[48] Real-World Outcomes of 2L ALK TKIs Following 1L Brigatinib for Patients with ALK plus NSCLC from the ALTA-1L Trial
Ahn, M. -J.
Delmonte, A.
Ghosh, S.
Hochmair, M.
Yang, T. -Y.
Yang, J. C. -H.
Han, J. -Y.
Hansen, K. Holmskov
Wu, Y.
Wan, Y.
Lin, H. M.
Kretz, J.
Hupf, B.
Kurec, A. M.
Churchill, E. N.
Fram, R. J.
Cabasag, C. J.
Goriya, V.
Zhao, Y.
Gemmen, E.
Campelo, M. R. Garcia
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S200 - S200
[49] Iruplinalkib in Patients with ALK-Positive CrizotinibResistant NSCLC: Updated Efficacy and Safety Data from a Phase 2 Trial
Shi, Y.
Chen, J.
Zhang, H.
Zhang, Z.
Zhang, Y.
Wang, Z.
Zhang, S.
Zhao, J.
Liu, C.
Wang, X.
Zhao, Y.
Hu, C.
Yang, L.
Hao, X.
Wang, L.
Liu, Y.
Yu, Y.
Zhao, J.
Wang, M.
Zhang, L.
Sun, S.
Hu, Y.
Gu, K.
Hang, X.
Shan, J.
Zhang, Y.
Tan, B.
Yang, W.
Yang, R.
Si, M.
Li, H.
Kang, X.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S203 - S203
[50] Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK plus NSCLC
Stinchcombe, Thomas E.
Doebele, Robert C.
Wang, Xiaofei
Gerber, David E.
Horn, Leora
Camidge, D. Ross
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : 156 - 161

← 1 2 3 4 5 →